The California-based biotech company's quarterly revenue rose 9% from a year earlier to $9.9 billion, which beat the average ...
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript February 3, 2026 Amgen Inc. beats earnings expectations. Reported ...
Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...
Amgen Inc. delivered strong operational performance across the board in 2025, and you can see that in the breadth of our business. Three of these, Repatha, Evenity, and TestSpire, all grew by more ...
Zacks Investment Research on MSN
Amgen (AMGN) is a top-ranked value stock: Should you buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein ...
Q. I developed severe depression while taking Repatha, the injectable cholesterol-lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...
We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. ...
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...
(Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results